Vanguard Group Inc Tyme Technologies, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$0.0 - $0.35 $0 - $1.39 Million	-3,967,720 Closed	0 $0
Q2 2022 Aug 12, 2022	BUY	$0.23 - $0.35 $21,703 - $33,027	94,365 Added 2.44%	3,967,720 $1.11 Million
Q1 2022 May 13, 2022	SELL	$0.28 - $0.68 $265,326 - $644,365	-947,596 Reduced 19.66%	3,873,355 $1.36 Million
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.04 $11,814 - $20,478	-19,691 Reduced 0.41%	4,820,951 $2.91 Million
Q3 2021 Nov 12, 2021	BUY	$0.99 - $1.38 $4,715 - $6,572	4,763 Added 0.1%	4,840,642 $4.99 Million
Q2 2021 Aug 13, 2021	BUY	$1.14 - $1.87 $5.51 Million - $9.04 Million	4,835,879 New	4,835,879 $6.09 Million

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.